Blueprint Medicines should be bought on any weakness, says Stifel
Keeping a Buy rating and $155 price target on Blueprint Medicines (BPMC), Stifel says the market is disappointed that 2025 Ayvakit guidance ...
ETF Daily News3d
Stifel Nicolaus Lowers Celsius (NASDAQ:CELH) Price Target to $37.00
Celsius (NASDAQ:CELH – Free Report) had its price objective reduced by Stifel Nicolaus from $45.00 to $37.00 in a research note released on Monday,Benzinga reports.They currently have a buy ...
Stifel Nicolaus Sticks to Its Hold Rating for ALX Oncology Holdings (ALXO)
In a report released today, Bradley Canino from Stifel Nicolaus maintained a Hold rating on ALX Oncology Holdings (ALXO – Research Report), ...